Fate Therapeutics Stock Forum

$Fate Therapeutics (FATE.US)$ Roche buying Fate too?

$Fate Therapeutics (FATE.US)$
Fate Therapeutics Presents 6-Month Follow-Up Data On First Patient Treated In Phase 1 Autoimmunity Study With Fludarabine-Free Conditioning And FT819 Off-The-Shelf, 1XX CAR T-Cell Product Candidate At ACR Convergence
27-year-old African American-Asian Woman with Active Lupus Nephritis Achieved DORIS Clinical Remission; Patient Remains On-study, in Clinical Remission, and Free of All Immunosuppressive Therapies
Patient Treated with Fludarabine-free Conditioning a...

$Fate Therapeutics (FATE.US)$
Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting
Fate Therapeutics (NASDAQ: FATE) presented initial clinical and preclinical data for FT825/ONO-8250, a CAR T-cell therapy targeting HER2 in advanced solid tumors. The Phase 1 study's first low-dose cohort of three heavily pre-treated patients showed favorable safety outcomes with ...

$Fate Therapeutics (FATE.US)$
Fate Therapeutics presented preclinical data for FT836, a novel CAR T-cell product candidate targeting MICA/B proteins expressed on cancer cells, at the 2024 SITC Annual Meeting. FT836 incorporates the company's Sword & Shield technology, designed to promote functional persistence without conditioning chemotherapy. The preclinical data demonstrated robust antigen-mediated expansion and durable anti-tumor activity across various solid tumors. The product uniquely ...

$Fate Therapeutics (FATE.US)$
Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting
Fate Therapeutics presented preclinical data for FT836, a novel CAR T-cell product candidate targeting MICA/B proteins expressed on cancer cells, at the 2024 SITC Annual Meeting. FT836 incorporates the company's Sword & Shield technology, designed to promote functional persistence without conditioning chemotherapy. The...

$Metagenomi Technologies, LLC (MGX.US)$ $Lantronix (LTRX.US)$
$Fate Therapeutics (FATE.US)$
$Navitas Semiconductor (NVTS.US)$
Opened up some positions on these today.
Increased $Rivian Automotive (RIVN.US)$ , $X4 Pharmaceuticals (XFOR.US)$
Took profit on $FTC Solar (FTCI.US)$ , $GigaCloud Technology (GCT.US)$ and $Aurora Innovation (AUR.US)$
I'll be back in GCT and AUR for sure.
Still looking at $Spero Therapeutics (SPRO.US)$ and $Acacia Research (ACTG.US)$ too.
Exciting day for dips!

$Fate Therapeutics (FATE.US)$
Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference
Fate Therapeutics, a clinical-stage biopharmaceutical company focusing on iPSC-derived cellular immunotherapies for cancer and autoimmune diseases, announced their participation in the 2024 Jefferies Global Healthcare Conference. The presentation is scheduled for June 5, 2024, at 3:00 PM ET in New York. The event will be webcasted live and accessible on the Company’s website, with an arch...

$Fate Therapeutics (FATE.US)$ Fate Therapeutics Treats First Lupus Patient In Phase 1 Study Of FT819 CAR T-Cell Therapy